Total Peripheral Nerve Injuries market size accounted for ~USD 2.4 billion in the 7MM in 2023

Peripheral Nerve Injuries (PNI) market across the seven major markets (7MM) - the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan - is positioned for strong growth over the forecast period. Valued at approximately USD 2.4 billion in 2023, the market is projected to expand significantly through 2034, supported by increasing incidence rates, surgical intervention volumes, and innovation in nerve repair technologies.

The United States continues to dominate the PNI market, accounting for nearly 1.7 million cases in 2023, the highest across the 7MM. Within the EU4 and the UK, Italy reported the highest burden of peripheral nerve injuries, followed by France, while Spain reported the lowest. Rising prevalence of traumatic injuries, motor vehicle accidents, occupational hazards, and sports-related trauma continue to be major contributors to the expanding patient pool.

In 2023, the annual number of upper-extremity PNI cases reached ~2.9 million, while lower-extremity injuries were approximately 1.1 million across the 7MM. Surgical intervention remains a cornerstone of treatment, aiming to repair damaged nerves, maximize axonal regeneration, and restore functional recovery. Correspondingly, nearly 1.7 million PNI surgeries were performed across the 7MM in 2023, highlighting the substantial therapeutic need.

Despite the availability of surgical techniques and biological conduits, unmet needs persist in achieving predictable nerve regeneration, restoring sensory and motor function, reducing recovery times, and minimizing long-term disability. Current repair strategies often face limitations such as incomplete regeneration, neuroma formation, and variable functional outcomes - creating significant opportunities for next-generation therapies and biomaterials.

The PNI market landscape is evolving with emerging regenerative medicine technologies and innovative therapeutic platforms. Notable advancements include:

• NTX-001 (Neuraptive Therapeutics) - received FDA Fast Track Designation in May 2020 and Orphan Drug Designation in January 2024 for peripheral nerve injury repair, underscoring its potential as a transformative therapy.
• CelGro® (Orthocell) - gained patent protection in Canada and Japan (February 2020), enabling broader commercialization of its collagen-based scaffold designed to enhance tissue repair in surgical and reconstructive applications.
• Avance® Nerve Graft - awarded Regenerative Medicine Advanced Therapy (RMAT) designation in October 2019, reinforcing its role as a leading biologic option in nerve repair.
  
  

With increasing adoption of biologic nerve grafts, advanced scaffolds, off-the-shelf conduits, and cell-based regenerative therapies, the future PNI market is poised for meaningful expansion. Continuous research aimed at improving axonal regrowth, functional recovery, and reinnervation outcomes is expected to drive therapeutic innovation through 2034.

Overall, the Peripheral Nerve Injuries market is on a strong growth trajectory, supported by rising injury incidence, high surgical volumes, expanding technological advancements, and increasing recognition of unmet clinical needs. As next-generation regenerative solutions advance through clinical development, the market is expected to transform significantly over the coming decade.

DelveInsight’s report, “Peripheral Nerve Injuries Market Insights, Epidemiology, and Market Forecast-2034,” provides an in-depth analysis of the evolving PNI landscape. The report offers comprehensive insights into epidemiology, market trends, current treatment practices, and emerging innovations across the 7MM - enabling stakeholders to make informed strategic, investment, and research decisions.

Some of the key facts of the Peripheral Nerve Injuries Market Report:

• The leading Peripheral Nerve Injuries Companies developing therapies include Neuraptive Therapeutics, Klisbio, Orthocell limited, Ono pharmaceutical, and others.
• Potential future therapies for Peripheral Nerve Injuries include Avance Nerve Graft, Nerbridge, NTX-001, SilkBridge, CelGro,  and others.
• The future of Peripheral Nerve Injuries treatment holds promise, driven by ongoing research and the development of innovative therapies. Current management strategies, such as symptomatic medications, physical therapy, and supportive care, remain essential.

Peripheral Nerve Injuries Overview

Peripheral nerve injuries (PNIs) refer to a broad range of conditions in which nerves outside the brain and spinal cord are damaged, impairing sensory perception, motor control, or organ function. These injuries commonly stem from traumatic events such as traffic accidents, falls, sports-related impacts, or penetrating trauma. They may also arise from nerve compression disorders, including carpal tunnel syndrome or other entrapment neuropathies, as well as systemic conditions like diabetes and autoimmune diseases that can compromise nerve integrity.

 

Clinical manifestations vary depending on the type and location of the injured nerve. Damage to sensory nerves may lead to numbness, tingling, pain, or abnormal sensations, whereas motor nerve injuries often cause muscle weakness, loss of movement, coordination difficulties, or muscle atrophy.

 

Diagnosis of PNIs usually requires a thorough clinical assessment, incorporating medical history review, physical examination, and specialized testing. Imaging modalities such as MRI or CT scans can help visualize structural abnormalities and pinpoint the injury site. Additionally, electrophysiological studies — including nerve conduction studies and electromyography — are essential for evaluating nerve function and determining the extent and severity of the damage.

Learn more about Peripheral Nerve Injuries treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Peripheral Nerve Injuries Treatment Market

Key Factors Driving Growth in the Peripheral Nerve Injuries Market

• Growing Peripheral Nerve Injuries Patient Population- In 2023, the seven major markets (7MM) recorded close to 4 million new peripheral nerve injury cases, with approximately 3 million involving the upper extremities and 1.1 million affecting the lower extremities. The surgical demand remains high, as nearly 1.7 million PNI-related procedures were performed during the same year. Increasing trauma incidence, orthopedic complications, and nerve damage following surgical interventions are projected to continue expanding the PNI patient population through 2034.

• Progress in PNI Clinical Trials & Regulatory Advancements- The therapeutic landscape for PNI is rapidly evolving, supported by active clinical development and favorable regulatory designations. In January 2024, the FDA awarded Orphan Drug Designation to Neuraptive Therapeutics’ NTX-001, building on its Fast Track Designation granted in 2020. Orthocell has fortified the position of its CelGro platform with patent approvals in Canada and Japan, and Axogen’s Avance Nerve Graft has received RMAT designation. Numerous Phase I–III clinical trials underway worldwide highlight the growing momentum behind innovative regenerative solutions aimed at improving functional nerve recovery.

• Innovative Therapies Transforming the PNI Treatment Landscape- Cutting-edge biologics and devices are reshaping the competitive environment in peripheral nerve repair. NTX-001 (Neuraptive Therapeutics) continues to advance as a promising adjunct in early nerve healing. SilkBridge (KLISBio) introduces a silk fibroin scaffold designed to enhance natural nerve regeneration, while Orthocell’s CelGro provides a flexible, biocompatible matrix to support tension-free nerve repair. These emerging technologies, alongside established solutions such as Avance Nerve Graft (Axogen) and Nerbridge (Toyobo), are expanding therapeutic options and elevating standards in peripheral nerve repair.

Recent Developments in Peripheral Nerve Injuries Clinical Trials:

• On December 3, 2025, the FDA officially approved Avance — an acellular nerve allograft scaffold — for use in the treatment of sensory nerve discontinuity, and expanded through the Accelerated Approval pathway to include motor and mixed nerve injuries, as well as sensory gaps of any length.
• In late 2025, the first patient was enrolled in a Phase 3 clinical trial of NTX-001 for upper-extremity nerve transections requiring surgical repair. The study is multicenter, randomized, blinded, and will compare NTX-001 plus standard surgical repair (neurorrhaphy) vs. standard repair alone. The trial plans to enroll ~110 patients across around 24 U.S. sites.

Learn more about the recent advancements in Peripheral Nerve Injuries treatment landscape @ Peripheral Nerve Injuries Recent Developments

 

Peripheral Nerve Injuries Epidemiology

• In the 7MM, the US accounted for the highest number of surgeries Peripheral Nerve Injuries, with nearly 770 thousand in 2023.

Peripheral Nerve Injuries Epidemiology Segmentation

• Total Peripheral Nerve Injuries Diagnosed Prevalent Cases
• Peripheral Nerve Injuries Gender-specific Diagnosed Prevalent Cases
• Peripheral Nerve Injuries Phenotype-specific Diagnosed Prevalent Cases
• Peripheral Nerve Injuries EDSS-specific Diagnosed Prevalent Cases

Peripheral Nerve Injuries Marketed Drugs

• Avance Nerve Graft: Axogen Corporation
• Nerbridge: Toyobo

 

Peripheral Nerve Injuries Emerging Drugs

• NTX-001: Neuraptive Therapeutics
• SilkBridge: KLISBio
• CelGro: Orthocell Limited

Peripheral Nerve Injuries Market Barriers

• Limited Regenerative Capacity & Unpredictable Clinical Outcomes- Peripheral nerve injuries often result in incomplete or slow functional recovery, even after surgical repair. Regeneration rates differ widely based on injury location, gap length, and patient comorbidities, resulting in variable sensory and motor outcomes. This unpredictability hampers consistent clinical adoption of newer biologics and device-based therapies.
• High Surgical Complexity and Need for Specialized Expertise- PNI repair requires advanced microsurgical skills, limiting access to high-quality treatment. Surgical outcomes depend heavily on the surgeon’s experience, availability of nerve repair specialists, and advanced infrastructure — all of which are unevenly distributed across the 7MM. This skill gap remains a significant barrier to optimal care.
• Delayed Diagnosis and Under-recognition of PNI Severity- In polytrauma cases, peripheral nerve injuries are frequently underdiagnosed or detected late, leading to delayed intervention and poorer functional recovery. Limited use of advanced imaging and electrophysiology in emergency settings further contributes to missed diagnoses.
• Limited Availability of Effective Off-the-Shelf Solutions- Although biologic grafts and synthetic conduits are emerging, the market still lacks widely accessible, standardized, and long-gap repair solutions. Autografts remain the gold standard but require donor-site nerve harvesting, causing additional morbidity and longer recovery times. These limitations restrict broad adoption of advanced graft technologies.

Request a free sample copy or view report summary: Peripheral Nerve Injuries Market Report

 

 

Scope of the Peripheral Nerve Injuries Market Report:

 

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Peripheral Nerve Injuries Companies: Neuraptive Therapeutics, Klisbio, Orthocell limited, Ono pharmaceutical, and others
• Key Peripheral Nerve Injuries Therapies: Avance Nerve Graft, Nerbridge, NTX-001, SilkBridge, CelGro, and others
• Peripheral Nerve Injuries Therapeutic Assessment: Peripheral Nerve Injuries current marketed and Peripheral Nerve Injuries emerging therapies
• Peripheral Nerve Injuries Market Dynamics: Peripheral Nerve Injuries market drivers and Peripheral Nerve Injuries market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Peripheral Nerve Injuries Unmet Needs, KOL’s views, Analyst’s views, Peripheral Nerve Injuries Market Access and Reimbursement

 

About DelveInsight

 

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.